New York, New York, United States Apple Tree Partners appeared to be the VC, which was created in 1999. The venture was found in North America in United States. The main department of described VC is located in the New York.
The fund has exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the most popular fund investment industries, there are Therapeutics, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Syntimmune, Chinook Therapeutics, Corvidia. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Besides them, we counted 4 critical employees of this fund in our database.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Apple Tree Partners, startups are often financed by Novartis Venture Fund, SR One, Roche Venture Fund. The meaningful sponsors for the fund in investment in the same round are SR One, Roche Venture Fund, Partners Innovation Fund. In the next rounds fund is usually obtained by Novartis Venture Fund, SR One, Roche Venture Fund.
The top activity for fund was in 2014. Opposing the other organizations, this Apple Tree Partners works on 3 percentage points less the average amount of lead investments. When the investment is from Apple Tree Partners the average startup value is 10-50 millions dollars. The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2019. Considering the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Brain Power | China, Guangdong, Shenzhen |
| Canopy Rivers | Canada, Ontario, Toronto |
| CHANEL | France, Ile-de-France, Neuilly-sur-seine |
| Chisage | China, Ningbo, Zhejiang |
| City National Bank | California, Los Angeles, United States |
| CRYSTAL VENTURES | - |
| Global Private Equity Group, LLC. | Salt Lake City, United States, Utah |
| Highland Capital | Bishkek, Kyrgyzstan |
| IDFC Mutual Fund | India, Maharashtra, Mumbai |
| Miteno | Beijing, Beijing, China |
| Ningbo Meishan Free Trade Port Zone Tianshuo Investment Management | China, Ningbo, Zhejiang |
| Octave Life Sciences | - |
| Orange Silicon Valley | California, San Francisco, United States |
| Senvest International | New York, New York, United States |
| Shanghai Gui Guo Assets Management Partnership | China, Shanghai |
| SXE Ventures | China, Hong Kong, Hong Kong Island |
| United States Council for Automotive Research | Michigan, Southfield, United States |
| WERU Investment | Chiyoda, Japan |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Deep Apple Therapeutics | $52M | 14 Dec 2023 | New York, New York, United States | ||
Ascidian Therapeutics | $40M | 08 Nov 2023 | Boston, Massachusetts, United States | ||
Aulos Bioscience | $20M | 01 Aug 2023 | Cambridge, Massachusetts, United States | ||
Initial Therapeutics | $75M | 01 May 2023 | New York, New York, United States | ||
Aethon Therapeutics | $30M | 09 Jan 2023 | New York, New York, United States | ||
Ascidian Therapeutics | $50M | 12 Oct 2022 | Boston, Massachusetts, United States | ||
Galvanize Therapeutics | $100M | 15 Sep 2022 | Menlo Park, California, United States | ||
Adendra Therapeutics | $54M | 07 Dec 2021 | London, England, United Kingdom | ||
Marengo Therapeutics | $80M | 08 Nov 2021 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Deep Apple Therapeutics | $52M | 14 Dec 2023 | New York, New York, United States | ||
Ascidian Therapeutics | $40M | 08 Nov 2023 | Boston, Massachusetts, United States | ||
Aulos Bioscience | $20M | 01 Aug 2023 | Cambridge, Massachusetts, United States | ||
Initial Therapeutics | $75M | 01 May 2023 | New York, New York, United States | ||
Aethon Therapeutics | $30M | 09 Jan 2023 | New York, New York, United States | ||
Ascidian Therapeutics | $50M | 12 Oct 2022 | Boston, Massachusetts, United States | ||
Galvanize Therapeutics | $100M | 15 Sep 2022 | Menlo Park, California, United States | ||
Adendra Therapeutics | $54M | 07 Dec 2021 | London, England, United Kingdom | ||
Marengo Therapeutics | $80M | 08 Nov 2021 | Cambridge, Massachusetts, United States |
